Atypical GTPases as drug targets

Anti-Cancer Agents in Medicinal Chemistry

Volumn 12, Issue 1, 2012, Pages 19-28

  Soundararajan, Meera ^a   Eswaran, Jeyanthy ^b  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b GEORGE WASHINGTON UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Anti cancer agents; Atypical GTPase; Drug target

Indexed keywords

2 (4 HYDROXYPHENYL) 4 MORPHOLINOPYRIDO[3',2':4,5]FURO[3,2 D]PYRIMIDINE; ANTIDIABETIC AGENT; ANTINEOPLASTIC AGENT; CALCIUM CALMODULIN DEPENDENT PROTEIN KINASE; CALCIUM CHANNEL; CALCIUM CHANNEL BLOCKING AGENT; CALCIUM CHANNEL L TYPE; CALCIUM ION; CENTAURIN; GUANINE NUCLEOTIDE BINDING PROTEIN; GUANOSINE TRIPHOSPHATASE; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ANTIDIABETIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; BRAIN TUMOR; CARCINOGENESIS; CYTOSKELETON; DIABETES MELLITUS; DRUG TARGETING; ENZYME STRUCTURE; GLIOBLASTOMA; HEART ARRHYTHMIA; HEART VENTRICLE HYPERTROPHY; HUMAN; HYPERTENSION; NEUROBLASTOMA; NEUROPATHIC PAIN; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PROTEIN FUNCTION; REGULATORY MECHANISM; REVIEW; SARCOMA; SIGNAL TRANSDUCTION; STROKE;

EID: 84855281884     PISSN: 18715206     EISSN: 18755992     Source Type: Journal    
DOI: 10.2174/187152012798764705     Document Type: Review

References (81)

1. Jaffe, A. B.; Hall, A. Rho GTPases: biochemistry and biology. Annu Rev Cell Dev Biol 2005, 21, 247-69.
2. Colicelli, J. Human RAS superfamily proteins and related GTPases. Sci STKE 2004, 2004 (250), RE13.
3. Sprang, S. R. G protein mechanisms: insights from structural analysis. Annu Rev Biochem 1997, 66, 639-78.
4. Wright, L. P.; Philips, M. R. Thematic review series: lipid posttranslational modifications. CAAX modification and membrane targeting of Ras. J Lipid Res 2006, 47 (5), 883-91.
5. Amor, J. C.; Harrison, D. H.; Kahn, R. A.; Ringe, D. Structure of the human ADP-ribosylation factor 1 complexed with GDP. Nature 1994, 372 (6507), 704-8.
6. Reynet, C.; Kahn, C. R. Rad: a member of the Ras family overexpressed in muscle of type II diabetic humans. Science 1993, 262 (5138), 1441-4.
7. Maguire, J.; Santoro, T.; Jensen, P.; Siebenlist, U.; Yewdell, J.; Kelly, K. Gem: an induced, immediate early protein belonging to the Ras family. Science 1994, 265 (5169), 241-4.
8. Finlin, B. S.; Andres, D. A. Rem is a new member of the Rad- and Gem/Kir Ras-related GTP-binding protein family repressed by lipopolysaccharide stimulation. J Biol Chem 1997, 272 (35), 21982-8.
9. Opatowsky, Y.; Sasson, Y.; Shaked, I.; Ward, Y.; Chomsky-Hecht, O.; Litvak, Y.; Selinger, Z.; Kelly, K.; Hirsch, J. A. Structurefunction studies of the G-domain from human gem, a novel small G-protein. FEBS Lett 2006, 580 (25), 5959-64.
10. Splingard, A.; Menetrey, J.; Perderiset, M.; Cicolari, J.; Regazzoni, K.; Hamoudi, F.; Cabanie, L.; El Marjou, A.; Wells, A.; Houdusse, A.; de Gunzburg, J. Biochemical and structural characterization of the gem GTPase. J Biol Chem 2007, 282 (3), 1905-15.
11. Beguin, P.; Mahalakshmi, R. N.; Nagashima, K.; Cher, D. H.; Kuwamura, N.; Yamada, Y.; Seino, Y.; Hunziker, W. Roles of 14-3-3 and calmodulin binding in subcellular localization and function of the small G-protein Rem2. Biochem J 2005, 390 (Pt 1), 67-75.
12. Beguin, P.; Mahalakshmi, R. N.; Nagashima, K.; Cher, D. H.; Takahashi, A.; Yamada, Y.; Seino, Y.; Hunziker, W. 14-3-3 and calmodulin control subcellular distribution of Kir/Gem and its regulation of cell shape and calcium channel activity. J Cell Sci 2005, 118 (Pt 9), 1923-34.
13. Fischer, R.; Wei, Y.; Anagli, J.; Berchtold, M. W. Calmodulin binds to and inhibits GTP binding of the ras-like GTPase Kir/Gem. J Biol Chem 1996, 271 (41), 25067-70.
14. Hall, A. Rho GTPases and the actin cytoskeleton. Science 1998, 279 (5350), 509-14.
15. Luo, L. Actin cytoskeleton regulation in neuronal morphogenesis and structural plasticity. Annu Rev Cell Dev Biol 2002, 18, 601-35.
16. Riento, K.; Ridley, A. J. Rocks: multifunctional kinases in cell behaviour. Nat Rev Mol Cell Biol 2003, 4 (6), 446-56.
17. Leone, A.; Mitsiades, N.; Ward, Y.; Spinelli, B.; Poulaki, V.; Tsokos, M.; Kelly, K. The Gem GTP-binding protein promotes morphological differentiation in neuroblastoma. Oncogene 2001, 20 (25), 3217-25.
18. Ward, Y.; Yap, S. F.; Ravichandran, V.; Matsumura, F.; Ito, M.; Spinelli, B.; Kelly, K. The GTP binding proteins Gem and Rad are negative regulators of the Rho-Rho kinase pathway. J Cell Biol 2002, 157 (2), 291-302.
19. Tseng, Y. H.; Vicent, D.; Zhu, J.; Niu, Y.; Adeyinka, A.; Moyers, J. S.; Watson, P. H.; Kahn, C. R. Regulation of growth and tumorigenicity of breast cancer cells by the low molecular weight GTPase Rad and nm23. Cancer Res 2001, 61 (5), 2071-9.
20. Missiaen, L.; Robberecht, W.; van den Bosch, L.; Callewaert, G.; Parys, J. B.; Wuytack, F.; Raeymaekers, L.; Nilius, B.; Eggermont, J.; De Smedt, H. Abnormal intracellular ca(2+)homeostasis and disease. Cell Calcium 2000, 28 (1), 1-21.
21. Isner, J. M. Myocardial gene therapy. Nature 2002, 415 (6868), 234-9.
22. Beguin, P.; Nagashima, K.; Gonoi, T.; Shibasaki, T.; Takahashi, K.; Kashima, Y.; Ozaki, N.; Geering, K.; Iwanaga, T.; Seino, S. Regulation of Ca2+ channel expression at the cell surface by the small G-protein kir/Gem. Nature 2001, 411 (6838), 701-6.
23. Finlin, B. S.; Crump, S. M.; Satin, J.; Andres, D. A. Regulation of voltage-gated calcium channel activity by the Rem and Rad GTPases. Proc Natl Acad Sci U S A 2003, 100 (24), 14469-74.
24. Fan, M.; Buraei, Z.; Luo, H. R.; Levenson-Palmer, R.; Yang, J. Direct inhibition of P/Q-type voltage-gated Ca2+ channels by Gem does not require a direct Gem/Cavbeta interaction. Proc Natl Acad Sci U S A 2010, 107 (33), 14887-92.
25. Fletcher, C. F.; Lutz, C. M.; O'Sullivan, T. N.; Shaughnessy, J. D., Jr.; Hawkes, R.; Frankel, W. N.; Copeland, N. G.; Jenkins, N. A. Absence epilepsy in tottering mutant mice is associated with calcium channel defects. Cell 1996, 87 (4), 607-17.
26. Jun, K.; Piedras-Renteria, E. S.; Smith, S. M.; Wheeler, D. B.; Lee, S. B.; Lee, T. G.; Chin, H.; Adams, M. E.; Scheller, R. H.; Tsien, R. W.; Shin, H. S. Ablation of P/Q-type Ca(2+) channel currents, altered synaptic transmission, and progressive ataxia in mice lacking the alpha(1A)-subunit. Proc Natl Acad Sci U S A 1999, 96 (26), 15245-50.
27. Cao, Y. Q. Voltage-gated calcium channels and pain. Pain 2006, 126 (1-3), 5-9.
28. Yaksh, T. L. Calcium channels as therapeutic targets in neuropathic pain. J Pain 2006, 7 (1 Suppl 1), S13-30.
29. Flynn, R.; Chen, L.; Hameed, S.; Spafford, J. D.; Zamponi, G. W. Molecular determinants of Rem2 regulation of N-type calcium channels. Biochem Biophys Res Commun 2008, 368 (3), 827-31.
30. Donath, M. Y.; Ehses, J. A.; Maedler, K.; Schumann, D. M.; Ellingsgaard, H.; Eppler, E.; Reinecke, M. Mechanisms of beta-cell death in type 2 diabetes. Diabetes 2005, 54 Suppl 2, S108-13.
31. Finlin, B. S.; Mosley, A. L.; Crump, S. M.; Correll, R. N.; Ozcan, S.; Satin, J.; Andres, D. A. Regulation of L-type Ca2+ channel activity and insulin secretion by the Rem2 GTPase. J Biol Chem 2005, 280 (51), 41864-71.
32. Seu, L.; Pitt, G. S. Dose-dependent and isoform-specific modulation of Ca2+ channels by RGK GTPases. J Gen Physiol 2006, 128 (5), 605-13.
33. Garvey, W. T.; Maianu, L.; Kennedy, A.; Wallace, P.; Ganaway, E.; Hamacher, L. L.; Yarnall, D. P.; Lenhard, J. M.; Burns, D. K. Muscle Rad expression and human metabolism: potential role of the novel Ras-related GTPase in energy expenditure and body composition. Diabetes 1997, 46 (3), 444-50.
34. Paulik, M. A.; Hamacher, L. L.; Yarnall, D. P.; Simmons, C. J.; Maianu, L.; Pratley, R. E.; Garvey, W. T.; Burns, D. K.; Lenhard, J. M. Identification of Rad's effector-binding domain, intracellular localization, and analysis of expression in Pima Indians. J Cell Biochem 1997, 65 (4), 527-41.
35. Yuan, X.; Yamada, K.; Ishiyama-Shigemoto, S.; Koyama, W.; Nonaka, K. Analysis of trinucleotide-repeat combination polymorphism at the rad gene in patients with type 2 diabetes mellitus. Metabolism 1999, 48 (2), 173-5.
36. Ilany, J.; Bilan, P. J.; Kapur, S.; Caldwell, J. S.; Patti, M. E.; Marette, A.; Kahn, C. R. Overexpression of Rad in muscle worsens diet-induced insulin resistance and glucose intolerance and lowers plasma triglyceride level. Proc Natl Acad Sci U S A 2006, 103 (12), 4481-6.
37. Zhang, J.; Chang, L.; Chen, C.; Zhang, M.; Luo, Y.; Hamblin, M.; Villacorta, L.; Xiong, J. W.; Chen, Y. E.; Zhu, X. Rad GTPase inhibits cardiac fibrosis through connective tissue growth factor. Cardiovasc Res 2011.
38. Murata, M.; Cingolani, E.; McDonald, A. D.; Donahue, J. K.; Marban, E. Creation of a genetic calcium channel blocker by targeted gem gene transfer in the heart. Circ Res 2004, 95 (4), 398-405.
39. Chang, L.; Zhang, J.; Tseng, Y. H.; Xie, C. Q.; Ilany, J.; Bruning, J. C.; Sun, Z.; Zhu, X.; Cui, T.; Youker, K. A.; Yang, Q.; Day, S. M.; Kahn, C. R.; Chen, Y. E. Rad GTPase deficiency leads to cardiac hypertrophy. Circulation 2007, 116 (25), 2976-83.
40. Ye, K.; Hurt, K. J.; Wu, F. Y.; Fang, M.; Luo, H. R.; Hong, J. J.; Blackshaw, S.; Ferris, C. D.; Snyder, S. H. Pike. A nuclear gtpase that enhances PI3kinase activity and is regulated by protein 4.1N. Cell 2000, 103 (6), 919-30.
41. Sedehizade, F.; Hanck, T.; Stricker, R.; Horstmayer, A.; Bernstein, H. G.; Reiser, G. Cellular expression and subcellular localization of the human Ins(1,3,4,5)P(4)-binding protein, p42(IP4), in human brain and in neuronal cells. Brain Res Mol Brain Res 2002, 99 (1), 1-11.
42. Aggensteiner, M.; Reiser, G. Expression of the brain-specific membrane adapter protein p42IP4/centaurin alpha, a Ins(1,3,4,5) P4/PtdIns(3,4,5)P3 binding protein, in developing rat brain. Brain Res Dev Brain Res 2003, 142 (1), 77-87.
43. Nie, Z.; Stanley, K. T.; Stauffer, S.; Jacques, K. M.; Hirsch, D. S.; Takei, J.; Randazzo, P. A. AGAP1, an endosome-associated, phosphoinositide-dependent ADP-ribosylation factor GTPaseactivating protein that affects actin cytoskeleton. J Biol Chem 2002, 277 (50), 48965-75.
44. Soundararajan, M.; Yang, X.; Elkins, J. M.; Sobott, F.; Doyle, D. A. The centaurin gamma-1 GTPase-like domain functions as an NTPase. Biochem J 2007, 401 (3), 679-88.
45. Cabedo, H.; Macian, F.; Villarroya, M.; Escudero, J. C.; Martinez-Vicente, M.; Knecht, E.; Armengod, M. E. The Escherichia coli trmE (mnmE) gene, involved in tRNA modification, codes for an evolutionarily conserved GTPase with unusual biochemical properties. EMBO J 1999, 18 (24), 7063-76.
46. Datta, S. R.; Dudek, H.; Tao, X.; Masters, S.; Fu, H.; Gotoh, Y.; Greenberg, M. E. Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell 1997, 91 (2), 231-41.
47. Cardone, M. H.; Roy, N.; Stennicke, H. R.; Salvesen, G. S.; Franke, T. F.; Stanbridge, E.; Frisch, S.; Reed, J. C. Regulation of cell death protease caspase-9 by phosphorylation. Science 1998, 282 (5392), 1318-21.
48. Brunet, A.; Bonni, A.; Zigmond, M. J.; Lin, M. Z.; Juo, P.; Hu, L. S.; Anderson, M. J.; Arden, K. C.; Blenis, J.; Greenberg, M. E. Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell 1999, 96 (6), 857-68.
49. Kane, L. P.; Shapiro, V. S.; Stokoe, D.; Weiss, A. Induction of NFkappaB by the Akt/PKB kinase. Curr Biol 1999, 9 (11), 601-4.
50. Tran, H.; Brunet, A.; Griffith, E. C.; Greenberg, M. E. The many forks in FOXO's road. Sci STKE 2003, 2003 (172), RE5.
51. Liu, X.; Hu, Y.; Hao, C.; Rempel, S. A.; Ye, K. PIKE-A is a protooncogene promoting cell growth, transformation and invasion. Oncogene 2007, 26 (34), 4918-27.
52. Ahn, J. Y.; Rong, R.; Liu, X.; Ye, K. PIKE/nuclear PI 3-kinase signaling mediates the antiapoptotic actions of NGF in the nucleus. EMBO J 2004, 23 (20), 3995-4006.
53. Ahn, J. Y.; Rong, R.; Kroll, T. G.; Van Meir, E. G.; Snyder, S. H.; Ye, K. PIKE (phosphatidylinositol 3-kinase enhancer)-A GTPase stimulates Akt activity and mediates cellular invasion. J Biol Chem 2004, 279 (16), 16441-51.
54. Elkahloun, A. G.; Krizman, D. B.; Wang, Z.; Hofmann, T. A.; Roe, B.; Meltzer, P. S. Transcript mapping in a 46-kb sequenced region at the core of 12q13.3 amplification in human cancers. Genomics 1997, 42 (2), 295-301.
55. Kim, H.; Huang, W.; Jiang, X.; Pennicooke, B.; Park, P. J.; Johnson, M. D. Integrative genome analysis reveals an oncomir/ oncogene cluster regulating glioblastoma survivorship. Proc Natl Acad Sci U S A 2010, 107 (5), 2183-8.
56. Chan, C. B.; Ye, K. PIKE GTPase are phosphoinositide-3-kinase enhancers, suppressing programmed cell death. J Cell Mol Med 2007, 11 (1), 39-53.
57. Persson, F.; Olofsson, A.; Sjogren, H.; Chebbo, N.; Nilsson, B.; Stenman, G.; Aman, P. Characterization of the 12q amplicons by high-resolution, oligonucleotide array CGH and expression analyses of a novel liposarcoma cell line. Cancer Lett 2008, 260 (1-2), 37-47.
58. Tang, X.; Feng, Y.; Ye, K. Src-family tyrosine kinase fyn phosphorylates phosphatidylinositol 3-kinase enhancer-activating Akt, preventing its apoptotic cleavage and promoting cell survival. Cell Death Differ 2007, 14 (2), 368-77.
59. Cerami, E.; Demir, E.; Schultz, N.; Taylor, B. S.; Sander, C. Automated network analysis identifies core pathways in glioblastoma. PLoS One 2010, 5 (2), e8918.
60. Cai, Y.; Wang, J.; Li, R.; Ayala, G.; Ittmann, M.; Liu, M. GGAP2/PIKE-a directly activates both the Akt and nuclear factorkappaB pathways and promotes prostate cancer progression. Cancer Res 2009, 69 (3), 819-27.
61. Tang, X.; Jang, S. W.; Okada, M.; Chan, C. B.; Feng, Y.; Liu, Y.; Luo, S. W.; Hong, Y.; Rama, N.; Xiong, W. C.; Mehlen, P.; Ye, K. Netrin-1 mediates neuronal survival through PIKE-L interaction with the dependence receptor UNC5B. Nat Cell Biol 2008, 10 (6), 698-706.
62. Harvey, R. C.; Mullighan, C. G.; Wang, X.; Dobbin, K. K.; Davidson, G. S.; Bedrick, E. J.; Chen, I. M.; Atlas, S. R.; Kang, H.; Ar, K.; Wilson, C. S.; Wharton, W.; Murphy, M.; Devidas, M.; Carroll, A. J.; Borowitz, M. J.; Bowman, W. P.; Downing, J. R.; Relling, M.; Yang, J.; Bhojwani, D.; Carroll, W. L.; Camitta, B.; Reaman, G. H.; Smith, M.; Hunger, S. P.; Willman, C. L. Identification of novel cluster groups in pediatric high-risk Bprecursor acute lymphoblastic leukemia with gene expression profiling: correlation with genome-wide DNA copy number alterations, clinical characteristics, and outcome. Blood 2010, 116 (23), 4874-84.
63. Nie, Z.; Boehm, M.; Boja, E. S.; Vass, W. C.; Bonifacino, J. S.; Fales, H. M.; Randazzo, P. A. Specific regulation of the adaptor protein complex AP-3 by the Arf GAP AGAP1. Dev Cell 2003, 5 (3), 513-21.
64. Weiner, D. M.; Levey, A. I.; Brann, M. R. Expression of muscarinic acetylcholine and dopamine receptor mRNAs in rat basal ganglia. Proc Natl Acad Sci U S A 1990, 87 (18), 7050-4.
65. Duttaroy, A.; Gomeza, J.; Gan, J. W.; Siddiqui, N.; Basile, A. S.; Harman, W. D.; Smith, P. L.; Felder, C. C.; Levey, A. I.; Wess, J. Evaluation of muscarinic agonist-induced analgesia in muscarinic acetylcholine receptor knockout mice. Mol Pharmacol 2002, 62 (5), 1084-93.
66. Yamada, M.; Lamping, K. G.; Duttaroy, A.; Zhang, W.; Cui, Y.; Bymaster, F. P.; McKinzie, D. L.; Felder, C. C.; Deng, C. X.; Faraci, F. M.; Wess, J. Cholinergic dilation of cerebral blood vessels is abolished in M(5) muscarinic acetylcholine receptor knockout mice. Proc Natl Acad Sci U S A 2001, 98 (24), 14096-101.
67. Basile, A. S.; Fedorova, I.; Zapata, A.; Liu, X.; Shippenberg, T.; Duttaroy, A.; Yamada, M.; Wess, J. Deletion of the M5 muscarinic acetylcholine receptor attenuates morphine reinforcement and withdrawal but not morphine analgesia. Proc Natl Acad Sci U S A 2002, 99 (17), 11452-7.
68. De Luca, V.; Wang, H.; Squassina, A.; Wong, G. W.; Yeomans, J.; Kennedy, J. L. Linkage of M5 muscarinic and alpha7-nicotinic receptor genes on 15q13 to schizophrenia. Neuropsychobiology 2004, 50 (2), 124-7.
69. Thomsen, M.; Woldbye, D. P.; Wortwein, G.; Fink-Jensen, A.; Wess, J.; Caine, S. B. Reduced cocaine self-administration in muscarinic 5 acetylcholine receptor-deficient mice. J Neurosci 2005, 25 (36), 8141-9.
70. Bendor, J.; Lizardi-Ortiz, J. E.; Westphalen, R. I.; Brandstetter, M.; Hemmings, H. C., Jr.; Sulzer, D.; Flajolet, M.; Greengard, P. AGAP1/AP-3-dependent endocytic recycling of M5 muscarinic receptors promotes dopamine release. EMBO J 2010, 29 (16), 2813-26.
71. Wassink, T. H.; Piven, J.; Vieland, V. J.; Jenkins, L.; Frantz, R.; Bartlett, C. W.; Goedken, R.; Childress, D.; Spence, M. A.; Smith, M.; Sheffield, V. C. Evaluation of the chromosome 2q37.3 gene CENTG2 as an autism susceptibility gene. Am J Med Genet B Neuropsychiatr Genet 2005, 136B (1), 36-44.
72. Moyers, J. S.; Zhu, J.; Kahn, C. R. Effects of phosphorylation on function of the Rad GTPase. Biochem J 1998, 333 (Pt 3), 609-14.
73. Finlin, B. S.; Andres, D. A. Phosphorylation-dependent association of the Ras-related GTP-binding protein Rem with 14-3-3 proteins. Arch Biochem Biophys 1999, 368 (2), 401-12.
74. Hennessy, B. T.; Smith, D. L.; Ram, P. T.; Lu, Y.; Mills, G. B. Exploiting the PI3K/AKT pathway for cancer drug discovery. Nat Rev Drug Discov 2005, 4 (12), 988-1004.
75. Garcia-Echeverria, C.; Sellers, W. R. Drug discovery approaches targeting the PI3K/Akt pathway in cancer. Oncogene 2008, 27 (41), 5511-26.
76. Workman, P.; Clarke, P. A.; Guillard, S.; Raynaud, F. I., Drugging the PI3 kinome. Nat Biotechnol 2006, 24 (7), 794-6.
77. Fan, Q. W.; Knight, Z. A.; Goldenberg, D. D.; Yu, W.; Mostov, K. E.; Stokoe, D.; Shokat, K. M.; Weiss, W. A. A dual PI3 kinase/mTOR inhibitor reveals emergent efficacy in glioma. Cancer Cell 2006, 9 (5), 341-9.
78. Dong, M.; Yan, B. P.; Liao, J. K.; Lam, Y. Y.; Yip, G. W.; Yu, C. M. Rho-kinase inhibition: a novel therapeutic target for the treatment of cardiovascular diseases. Drug Discov Today 2010, 15 (15-16), 622-9.
79. Zhou, Q.; Gensch, C.; Liao, J. K. Rho-associated coiled-coilforming kinases (ROCKs): potential targets for the treatment of atherosclerosis and vascular disease. Trends Pharmacol Sci 2011, 32 (3), 167-73.
80. Huentelman, M. J.; Stephan, D. A.; Talboom, J.; Corneveaux, J. J.; Reiman, D. M.; Gerber, J. D.; Barnes, C. A.; Alexander, G. E.; Reiman, E. M.; Bimonte-Nelson, H. A. Peripheral delivery of a ROCK inhibitor improves learning and working memory. Behav Neurosci 2009, 123 (1), 218-23.
81. Sasaki, Y.; Suzuki, M.; Hidaka, H. The novel and specific Rho-kinase inhibitor (S)-(+)-2-methyl-1-[(4-methyl-5-isoquinoline) sulfonyl]-homopiperazine as a probing molecule for Rho-kinaseinvolved pathway. Pharmacol Ther 2002, 93 (2-3), 225-32.